Annuncio pubblicitario
Italia markets close in 4 hours 57 minutes

  • FTSE MIB

    34.390,21
    +26,46 (+0,08%)
     

  • Dow Jones

    38.503,69
    +263,71 (+0,69%)
     

  • Nasdaq

    15.696,64
    +245,33 (+1,59%)
     

  • Nikkei 225

    38.460,08
    +907,92 (+2,42%)
     

  • Petrolio

    82,99
    -0,37 (-0,44%)
     

  • Bitcoin EUR

    62.073,56
    +193,70 (+0,31%)
     

  • CMC Crypto 200

    1.431,48
    +7,38 (+0,52%)
     

  • Oro

    2.331,20
    -10,90 (-0,47%)
     

  • EUR/USD

    1,0693
    -0,0011 (-0,11%)
     

  • S&P 500

    5.070,55
    +59,95 (+1,20%)
     

  • HANG SENG

    17.201,27
    +372,34 (+2,21%)
     

  • Euro Stoxx 50

    5.028,47
    +20,30 (+0,41%)
     

  • EUR/GBP

    0,8593
    -0,0002 (-0,03%)
     

  • EUR/CHF

    0,9771
    +0,0016 (+0,16%)
     

  • EUR/CAD

    1,4623
    +0,0005 (+0,04%)
     

Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

Abeona Therapeutics Inc.
·1 minuto per la lettura
Abeona Therapeutics Inc.
Abeona Therapeutics Inc.

NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 8:30 a.m. ET. The Company will also participate in one-on-one investor meetings at the conference.

A live webcast of the fireside chat will be available on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events. The webcast will be archived for 30 days. Those interested in attending the fireside chat or requesting a one-on-one meeting with Abeona are encouraged to contact their Jefferies representative.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s lead clinical program is EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Abeona’s fully integrated cell and gene therapy cGMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and potential commercial production of AAV-based gene therapies. For more information, visit www.abeonatherapeutics.com.

CONTACT: Investor and Media Contact: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com